SWITZERLAND, THURSDAY, 7 MAY 2020 10:00 PM CET
As the world’s first AI-biopharma company that has discovered and publicized the precise aetiology and pathology of COVID-191, we are committed to the non-profit dissemination of our COVID-19 discoveries and the public validation of our COVID-19 clinical predictions.
We have conducted comprehensive functional analyses of the diverse mutations of more than 4000 SARS-CoV-2 viral isolates available at GISAID2 and other public sources3,4. We hereby present the following pathology-based clinical predictions that the diverse mutations converge upon increasing infectivity of SARS-CoV-2 and increasing severity of COVID-19:
The diverse mutations of the SARS-CoV-2 genome have enhanced both viral replication and viral spread consistent with the unbiased survival strategy of SARS-CoV-21. In particular, the mutated SARS-CoV-2 strains could exert a more potent suppression of both the innate and the adaptive antiviral immune response upon their successful entry into host cells, resulting in a further increase in the peak viral load and a further delay of the first symptom onset.
Furthermore, the diverse mutations of the SARS-CoV-2 genome have enhanced the differential hematologic complications in young and elderly patients5,6. In particular, the mutated SARS-CoV-2 strains could increasingly cause hematologic adaptive hyperinflammation in young COVID-19 patients at the early stage of disease progression, resulting in severe complications such as thrombophilia and necrotizing vasculitis. In contrast, the mutated SARS-CoV-2 strains could increasingly cause hematologic innate hyperinflammation in elderly COVID-19 patients at the late stage of disease progression, resulting in severe complications such as purpura.
In summary, we predict that the diverse mutations of SARS-CoV-2 converge upon compensatory mechanisms that lead to longer viral sheddings, higher peak viral loads, worse clinical progressions, severer hematological complications, faster mutation rates, accelerated host aging, and more persistent infections.
As young and elderly populations are increasingly vulnerable to mutated SARS-CoV-2 strains, protective measures such as social distancing and online classrooms should not be relaxed.
The rational discovery of unbiased COVID-19 treatments and vaccines that target the exact mechanisms for both viral replication and host immunomodulation reinforced by SARS-CoV-2 mutations may be the only effective means to put an end to the COVID-19 pandemic.
1. Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+Etoposide Combination Therapy for Critically Ill COVID-19 Patients. (2020). doi:10.20944/PREPRINTS202003.0341.V1
2. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob. Challenges 1, 33–46 (2017).
3. Yao, H. et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv 2020.04.14.20060160 (2020). doi:10.1101/2020.04.14.20060160
4. Su, Y. C. F. et al. Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. bioRxiv 2020.03.11.987222 (2020). doi:10.1101/2020.03.11.987222
5. Zulfiqar, A.-A., Lorenzo-Villalba, N., Hassler, P. & Andrès, E. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N. Engl. J. Med. 43, e43 (2020).
6. Bowles, L. et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N. Engl. J. Med. (2020). doi:10.1056/NEJMc2013656
About Demiurge Technologies AG
Demiurge Technologies is a research-based AI-biopharmaceutical company that transforms publicly available life science data into precise disease models in areas with unmet medical needs. The company pioneers a self-correcting scientific approach that validates disease models with the accuracy of AI-based predictions of phase 3 clinical trial outcomes. The company also pioneers a self-sustaining business that commercializes disease models by accelerating the AI-based discovery and development of innovative medicines. Demiurge started in 2016 with headquarters in Switzerland.
AI has been an emerging powerful approach to deeper disease understanding and faster drug discovery, yet it must be put to the most rigorous test to prove its worth under public scrutiny. Demiurge has predicted the outcomes of more than 90 phase 3 clinical trials across multiple therapeutic areas and achieved more than 80% accuracy. Furthermore, we have been inviting the public to witness our future predictions of clinical trial outcomes on Twitter (@DemiurgeTech).
Therefore, we officially put forward AI-based discoveries of the complete aetiology and pathology of COVID-19 and the candidate treatments for COVID-19 as scientific hypotheses only and invite the world to validate their potential to solve the unprecedented global crisis posed by COVID-19.
This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and may not match the actual scale. This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘predicts’, ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’,‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward-looking statements or other information contained in this presentation. You should not view information related to the past performance of Demiurge and its affiliates or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments, and consequently totals may not appear to sum. None of the information in this presentation does, by itself, constitute an offering or an offering circular according to Article 652a of the Swiss Code of Obligations and is subject to change without notice. Any offer or solicitation with respect to any securities that may be issued by Demiurge will be made only by means of definitive offering memoranda or prospectus, which will be provided to prospective investors and will contain material information that is not set forth herein, including risk factors relating to any such investment. Before making an investment, you must obtain and carefully read all information needed to evaluate the investment, including, but not limited to the documents providing important disclosures regarding risks, fees and expenses. An investment in Demiurge may be volatile and can suffer from adverse or unexpected market moves or other adverse events. Investors may suffer the loss of their entire investment. An investment in Demiurge will be discrete from an investment in any funds or other investment programs managed by Demiurge and the results or performance of such other investment programs is not indicative of the results or performance that will be achieved by Demiurge or such investment programs.